<div id="readability-page-1"><div> <div>, /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (&#34;Volition&#34;), a multi-national epigenetics company, today announces two oral presentations featuring its Nu.Q® Vet Cancer Test at the Asian Meeting of Animal Medicine Specialties (AMAMS 2025), a premier event bringing together leading veterinary professionals and experts from across Asia.The two presentations feature results from two clinical studies conducted by Dr Masahiko Sato, DVM, PhD, DACVIM (SAIM), DAiCVIM (IM) in conjunction with FujiFilm Vet Systems. Dr Sato, a key opinion leader is Chief of Internal Medicine Service at the Veterinary Specialists Emergency Center, one of the largest referral hospitals in Japan.AMAMS 2025 is taking place in Thailand.Commenting on the results Dr Sato said:&#34;The Nu.Q® Vet Cancer Test may serve as a valuable diagnostic tool, particularly for differentiating between benign and malignant conditions such as Canine Chronic Enteropathy and Gastrointestinal Lymphoma.&#34;Kiyotaka Fujiwara, Chief Operating Officer at Fujifilm Vet Systems, added:&#34;We are delighted that leading veterinarian Dr Sato has adopted the Nu.Q® Vet Cancer Test in Japan, and not only researching, but publishing specific use cases. We believe this will further raise the awareness of the test and drive wider adoption.&#34;The presentations:Title: &#34;Diagnostic Utility of Plasma Nucleosome Concentration in Differentiating Canine Chronic Enteropathy from Gastrointestinal Lymphoma&#34; Presenter: Kentaro Nabeshima Date and Time:Thursday, June 5, 2025, 1:40PM – 1:50PM (ICT) Venue: Room 108 Key Conclusion: Nu.Q® Vet Cancer Test may serve as a valuable diagnostic tool for distinguishing CE from GIL, with particularly high levels observed in medium-to-large cell GIL. Title: &#34;Evaluation of Plasma Nucleosome Concentrations as a Biomarker for Canine Nasal Tumors&#34; Presenter: Chihoko Takahashi Date and Time:Thursday, June 5, 2025, 3:30PM – 3:40PM (ICT) Venue:Room 108About Volition Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com+44 (0) 7557 774620Investor Relations: Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com+1-212-915-2568Safe Harbor StatementStatements in this press release may be &#34;forward-looking statements&#34; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as &#34;expects,&#34; &#34;anticipates,&#34; &#34;intends,&#34; &#34;plans,&#34; &#34;aims,&#34; &#34;targets,&#34; &#34;believes,&#34; &#34;seeks,&#34; &#34;estimates,&#34; &#34;optimizing,&#34; &#34;potential,&#34; &#34;goal,&#34; &#34;suggests,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;may,&#34; &#34;will&#34; and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, the exercise of the milestone-linked warrants upon the achievement of such milestone events or otherwise prior to their expiration, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, the effectiveness of Volition's cost reduction measures, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to &#34;$&#34; refer to the legal currency of the United States of America.SOURCE VolitionRx Limited</div> </div></div>

VNRX

VolitionRx Limited (NYSE AMERICAN: VNRX) announced two oral presentations at the Asian Meeting of Animal Medicine Specialties (AMAMS 2025) in Thailand, showcasing its Nu.Q® Vet Cancer Test. The presentations, led by Dr. Masahiko Sato, focus on differentiating between benign and malignant conditions in canines. Key findings suggest the test may effectively distinguish Canine Chronic Enteropathy from Gastrointestinal Lymphoma. The event highlights Volition's commitment to advancing epigenetics and improving diagnostic tools for veterinary medicine.

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties | VNRX Stock News